821 related articles for article (PubMed ID: 25546985)
1. [Comparison of the safety of rivaroxaban versus dabigatran therapy in patients with persistent atrial fibrillation].
Gorzelak-Pabiś P; Duraj I; Szlagowska L; Ciastkowska A; Broncel M
Pol Merkur Lekarski; 2014 Nov; 37(221):261-4. PubMed ID: 25546985
[TBL] [Abstract][Full Text] [Related]
2. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.
Mantha S; Ansell J
Thromb Haemost; 2012 Sep; 108(3):476-84. PubMed ID: 22740145
[TBL] [Abstract][Full Text] [Related]
3. Rivaroxaban and dabigatran in patients undergoing catheter ablation of atrial fibrillation.
Providência R; Marijon E; Albenque JP; Combes S; Combes N; Jourda F; Hireche H; Morais J; Boveda S
Europace; 2014 Aug; 16(8):1137-44. PubMed ID: 24550347
[TBL] [Abstract][Full Text] [Related]
4. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
Cheng JW; Barillari G
J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study.
Maura G; Blotière PO; Bouillon K; Billionnet C; Ricordeau P; Alla F; Zureik M
Circulation; 2015 Sep; 132(13):1252-60. PubMed ID: 26199338
[TBL] [Abstract][Full Text] [Related]
6. Meta-analysis of efficacy and safety of rivaroxaban compared with warfarin or dabigatran in patients undergoing catheter ablation for atrial fibrillation.
Aryal MR; Ukaigwe A; Pandit A; Karmacharya P; Pradhan R; Mainali NR; Pathak R; Jalota L; Bhandari Y; Donato A
Am J Cardiol; 2014 Aug; 114(4):577-82. PubMed ID: 24998087
[TBL] [Abstract][Full Text] [Related]
7. Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis.
Harenberg J; Marx S; Diener HC; Lip GY; Marder VJ; Wehling M; Weiss C
Int Angiol; 2012 Aug; 31(4):330-9. PubMed ID: 22801398
[TBL] [Abstract][Full Text] [Related]
8. Safety of new oral anticoagulants for patients undergoing atrial fibrillation ablation.
Stepanyan G; Badhwar N; Lee RJ; Marcus GM; Lee BK; Tseng ZH; Vedantham V; Olgin J; Scheinman M; Gerstenfeld EP
J Interv Card Electrophysiol; 2014 Jun; 40(1):33-8. PubMed ID: 24643666
[TBL] [Abstract][Full Text] [Related]
9. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.
Lip GY; Larsen TB; Skjøth F; Rasmussen LH
J Am Coll Cardiol; 2012 Aug; 60(8):738-46. PubMed ID: 22575324
[TBL] [Abstract][Full Text] [Related]
10. Risk of major bleeding in different indications for new oral anticoagulants: insights from a meta-analysis of approved dosages from 50 randomized trials.
Sardar P; Chatterjee S; Lavie CJ; Giri JS; Ghosh J; Mukherjee D; Lip GY
Int J Cardiol; 2015 Jan; 179():279-87. PubMed ID: 25464465
[TBL] [Abstract][Full Text] [Related]
11. {blacktriangledown} Apixaban and {blacktriangledown} rivaroxaban for stroke prevention in AF.
Drug Ther Bull; 2014 Jan; 52(1):6-9. PubMed ID: 24401533
[TBL] [Abstract][Full Text] [Related]
12. Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis.
Chan KE; Edelman ER; Wenger JB; Thadhani RI; Maddux FW
Circulation; 2015 Mar; 131(11):972-9. PubMed ID: 25595139
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation.
Lip GY; Kongnakorn T; Phatak H; Kuznik A; Lanitis T; Liu LZ; Iloeje U; Hernandez L; Dorian P
Clin Ther; 2014 Feb; 36(2):192-210.e20. PubMed ID: 24508420
[TBL] [Abstract][Full Text] [Related]
14. Dabigatran, ROCKET atrial fibrillation, and beyond: basic science, mechanisms of agents, monitoring, and reversal.
Bauer KA
Stroke; 2013 Jun; 44(6 Suppl 1):S38-40. PubMed ID: 23709725
[No Abstract] [Full Text] [Related]
15. Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study.
Abraham NS; Singh S; Alexander GC; Heien H; Haas LR; Crown W; Shah ND
BMJ; 2015 Apr; 350():h1857. PubMed ID: 25910928
[TBL] [Abstract][Full Text] [Related]
16. A new era of oral anticoagulation in atrial fibrillation: implications in clinical practice.
Kasmeridis C; Lip GY; Apostolakis S
Hosp Pract (1995); 2013 Feb; 41(1):61-70. PubMed ID: 23466968
[TBL] [Abstract][Full Text] [Related]
17. Dabigatran for stroke prevention in nonvalvular atrial fibrillation: focus in the geriatric population.
Brunetti L; Chen C; White J
Consult Pharm; 2014 Mar; 29(3):169-78. PubMed ID: 24589766
[TBL] [Abstract][Full Text] [Related]
18. Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the working group on perioperative haemostasis (GIHP) - March 2013.
Pernod G; Albaladejo P; Godier A; Samama CM; Susen S; Gruel Y; Blais N; Fontana P; Cohen A; Llau JV; Rosencher N; Schved JF; de Maistre E; Samama MM; Mismetti P; Sié P;
Arch Cardiovasc Dis; 2013; 106(6-7):382-93. PubMed ID: 23810130
[TBL] [Abstract][Full Text] [Related]
19. Bleeding with dabigatran, rivaroxaban, apixaban. No antidote, and little clinical experience.
Prescrire Int; 2013 Jun; 22(139):155-9. PubMed ID: 23866358
[TBL] [Abstract][Full Text] [Related]
20. Major bleeding with dabigatran and rivaroxaban in patients with atrial fibrillation: a real-world setting.
Fontaine GV; Mathews KD; Woller SC; Stevens SM; Lloyd JF; Evans RS
Clin Appl Thromb Hemost; 2014 Oct; 20(7):665-72. PubMed ID: 24875781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
